Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Operational Update

7 Jul 2014 07:00

RNS Number : 5184L
Fastnet Oil & Gas PLC
07 July 2014
 



7 July 2014

Fastnet Oil & Gas plc

("Fastnet" or the "Company")

 

FASTNET IMPROVES TERMS OF AND EXTENDS EXCLUSIVE OPTION AGREEMENT TO FARM INTO THE TENDRARA LAKBIR PETROLEUM AGREEMENT ONSHORE MOROCCO AND PROVIDES OPERATIONAL UPDATE

 

Fastnet (AIM: FAST, ESM: FOI), the UK and Irish listed E&P company focussed on near term exploration and appraisal acreage in Morocco and the Celtic Sea, is pleased to announce that its wholly owned subsidiary Pathfinder Hydrocarbon Ventures Limited ("Pathfinder") has entered into an amended exclusive option agreement with Oil and Gas Investments Funds ("OGIF") (the "Option Agreement"), in relation to eight Exploration Permits comprising the Tendrara Lakbir Petroleum Agreement (the "Tendrara Licence") onshore Morocco.

Following substantive negotiations with its partner OGIF, Fastnet has secured improved commercial terms from those previously announced on 29 May 2013. These include:

· Extension of the Option Agreement to 31 December 2014

· Fastnet's net equity interest increased from 37.5% to 50% upon the option being exercised and subject to the necessary Moroccan Government approvals

· Fastnet will carry OGIF in the first well required during the Initial Period of the Tendrara Licence

· At Fastnet's election, Fastnet will carry OGIF for a well on the TE-5 Structure, or an exploration well on any alternative gas prospect and/or existing gas discovery in the Tendrara Licence Area as required by the committed work programme of the First Extension Period 

· This reduces the drilling commitments under the original Option Agreement, which involved carrying OGIF in three wells; the first well plus two additional appraisal/exploration wells by 1 April 2015 and 1 April 2018, respectively

· The deadline to drill the first well has been extended from 30 September 2014 to 21 April 2015. The time in between exercising the Option Agreement and the drilling deadline allows Fastnet to acquire its net equity interest in the Tendrara Licence and Association Contract prior to commencing the drilling programme as the designated operator 

· Fastnet will be required to provide OGIF with an executed drilling contract or alternatively an irrevocable bank guarantee of USD$2.75 million 

Operational Update

In addition the revised commercial terms under the Option Agreement described above, Fastnet is also pleased to provide the following operational update in relation to the Tendrara Licence:

· Reservoir engineering studies have been completed and currently the new Pre-Stack Seismic Depth Migrations are being interpreted to select final drilling locations and to finalise well design

 

· Well planning, rig selection and environmental impact studies are ongoing and will be completed during this calendar year

 

· In order to accelerate monetisation of the TE-5 gas asset, Fastnet is seeking an additional drilling partner, with onshore gas development experience, to facilitate executing a drilling programme that will target materially higher potential gross gas resources; the gross unrisked High Estimate gas resources for the TE-5 Structure are 891.9 BCF. The Best Estimate gas resources, targeted by the original proposed drilling programme, are 310.5 BCF

 

· Discussions with suitably qualified potential partners, who have all expressed an interest in participating in a potential gas development, are underway and are expected to conclude in H2 2014

Paul Griffiths, Managing Director of Fastnet, commented:

"The revised terms significantly reduce Fastnet's financial exposure and provide us with much improved project economics. The process of bringing in an additional partner is underway. We expect that the new commercial terms and project economics should allow us to attract a major partner, with experience in developing and monetising onshore gas discoveries, by offering sufficient equity, whilst maintaining a material equity level for Fastnet shareholders as we seek to target materially higher potential gas resources in the planned drilling programme. We maintain our strategy of prudently managing our cash resources as we did through our successful Foum Assaka farm-out, which de-risked our financial exposure to the drilling costs. We believe that the Tendrara Licence is highly attractive to a potential strategic gas partner given the existing TE-5 gas discovery with near term development potential, and the additional prospectivity of multiple play types within the large licence area which provides significant potential upside."

For further information, please contact:

Fastnet Oil & Gas plc

Cathal Friel, Chairman

Paul Griffiths, Managing Director

+353 (1) 644 0007

Shore Capital

Nomad

Bidhi Bhoma, Edward Mansfield

Corporate Broking

Jerry Keen

+44 (0) 20 7408 4090

 

GMP Securities Europe LLP

(Joint Broker)

Rob Collins, Emily Morris, Liz Williamson

 

+44 (20) 20 7467 2800

Davy

(ESM Adviser & Joint Broker)

John Frain

Anthony Farrell

 

 +353 (1) 679 6363

Bell Pottinger

Philip Dennis, Rollo Crichton-Stuart, Jimmy Lea

 

 +44 (0) 207 861 3232

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFZLFBZDFEBBV
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.